Role of intestinal oxidative metabolism on first pass effect
肠道氧化代谢对首过效应的作用
基本信息
- 批准号:09470496
- 负责人:
- 金额:$ 4.93万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (B)
- 财政年份:1997
- 资助国家:日本
- 起止时间:1997 至 1998
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
In rabbit Intestine, the expression of CYP1A, CYP2C, CYP2D and CYP3A proteins was detected by immuno blot analyses, and CYP3A forms were found to be induced by rifampicin.Five components were isolated from grapefruit juice that inhibit human CYP3A-mediated drug oxidation. They include two furocoumarin dimers (GF-I-1 and GF-I-4) which are strong candi-dates for causative agents of grapefruit juice-mediated drug interaction.Addition of ethyl acetate extract of grapefruit juice Into an incubation mixture resulted in decreased activities of CYP3A4, CYP1A2, CYP2C9, CYP2C19 and CYP2D6. The furocoumarins clearly Inhibited CYP3A4-catalyzed nifedipine oxidation in dose- and time-dependent manners, suggesting that these compounds are mechanism-based inhibitors of CYP3A4. Of the furocoumarin investigated, furocoumarin dimers, GF-I-1 and GF-I-4, were the most potent inhibitors of CYP3A4.To determine the effect of grapefruit juice on omeprazole metabolism in vivo, omeprazole was taken orally by 13 healthy volunteers. AUC ratio of omeprazole sulfone to omeprazole, index of CYP3A4 activity, was decreased 33% (p< 0.001) by grapefruit juice intake whereas AUC ratio of 5-hydroxyomeprazole to omeprazole, index of liver-specific expressed CYP2C 19 activity, did not differ between two experiments. These data suggest that effect of grapefruit juice may confine within gastrointestinal tract, and not extend to hepatic P450s.
免疫印迹法检测兔肠组织中CYP1A、CYP2C、CYP2D和CYP3A蛋白的表达,发现利福平诱导了CYP3A蛋白的表达。从葡萄柚汁中分离到5个抑制人cyp3a介导的药物氧化的成分。它们包括两种呋喃香豆素二聚体(GF-I-1和GF-I-4),它们是葡萄柚汁介导的药物相互作用的强候选病原体。在培养液中加入葡萄柚汁乙酸乙酯提取物,导致CYP3A4、CYP1A2、CYP2C9、CYP2C19和CYP2D6的活性降低。呋喃香豆素明显抑制CYP3A4催化的硝苯地平氧化,呈剂量和时间依赖性,表明这些化合物是基于机制的CYP3A4抑制剂。在研究的呋喃香豆素中,呋喃香豆素二聚体GF-I-1和GF-I-4是CYP3A4最有效的抑制剂。为了确定葡萄柚汁对体内奥美拉唑代谢的影响,13名健康志愿者口服奥美拉唑。摄入葡萄柚汁后,奥美拉唑砜与奥美拉唑的AUC比(CYP3A4活性指数)降低了33% (p< 0.001),而5-羟基奥美拉唑与奥美拉唑的AUC比(肝脏特异性表达CYP2C 19活性指数)在两个实验中没有差异。这些数据表明,西柚汁的作用可能局限于胃肠道,而不会扩展到肝脏p450。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
永田 清: "ヒトP450分子種のin vitro同定法と問題点" 医学のあゆみ. 182. 807-811 (1997)
Kiyoshi Nagata:“人类P450分子种类的体外鉴定方法和问题”医学史182。807-811(1997)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
K.Fukuda: "Grapefruitcomponent interacting with rat and human P450 CYP3A : possible involvement of non-flavonoid component in drug interac tion" Biol.Pharm.Bull.20. 560-564 (1997)
K.Fukuda:“葡萄柚成分与大鼠和人类 P450 CYP3A 相互作用:非类黄酮成分可能参与药物相互作用”Biol.Pharm.Bull.20。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
K.Fukuda: "Specific CYP3A4 inhibitors in grapefruit juice : furocoumarin dimers as components of drug interaction" Pharmacogenetics. 7. 391-396 (1997)
K.Fukuda:“葡萄柚汁中的特定 CYP3A4 抑制剂:呋喃香豆素二聚体作为药物相互作用的组成部分”药物遗传学。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YAMAZOE Yasushi其他文献
YAMAZOE Yasushi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YAMAZOE Yasushi', 18)}}的其他基金
CYP3A4 induction-associated dyslipidemia : a new risk factor for lifestyle disease
CYP3A4诱导相关的血脂异常:生活方式病的新危险因素
- 批准号:
22659028 - 财政年份:2010
- 资助金额:
$ 4.93万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Regulation of hepatic lipid metabolism through ileal bile acid-FGF signaling
通过回肠胆汁酸-FGF信号调节肝脏脂质代谢
- 批准号:
21390039 - 财政年份:2009
- 资助金额:
$ 4.93万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mechanisms for delayed organ toxicity induced by drug and prediction system using comprehensive analysis
药物迟发性器官毒性机制及综合分析预测系统
- 批准号:
19390037 - 财政年份:2007
- 资助金额:
$ 4.93万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mechanism for human-specific hepatotoxicity and development of prediction system
人类特异性肝毒性机制及预测系统开发
- 批准号:
17390039 - 财政年份:2005
- 资助金额:
$ 4.93万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Bile acids, key compounds for the mechanistic analyses of hepatotoxicity, and nuclear receptor interaction
胆汁酸,肝毒性机制分析和核受体相互作用的关键化合物
- 批准号:
15390043 - 财政年份:2003
- 资助金额:
$ 4.93万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Human characteristic mechanism of enzyme induction and the prediction
人体特有的酶诱导机制及预测
- 批准号:
13470510 - 财政年份:2001
- 资助金额:
$ 4.93万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Grapefruit juice-drug interaction and the prediction
葡萄柚汁与药物的相互作用及预测
- 批准号:
12557225 - 财政年份:2000
- 资助金额:
$ 4.93万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of as table expression system for human drug metabolizing enzymes
人药物代谢酶as表表达系统的开发
- 批准号:
07557149 - 财政年份:1995
- 资助金额:
$ 4.93万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Analysis of mechanism of neonatal imprinting of drug-metabolizing enzymes of rat liver
大鼠肝脏药物代谢酶新生期印记机制分析
- 批准号:
60480130 - 财政年份:1985
- 资助金额:
$ 4.93万 - 项目类别:
Grant-in-Aid for General Scientific Research (B)
相似海外基金
PHARMACOKINETIC AND PHARMACODYNAMIC TRIALS FOR MEDICATION DEVELOPMENT IN SUD. TO1 PHASE 1 COCAINE DRUG INTERACTION SEPTEMBER 25, 2023 TO MARCH 24, 2025. N01DA-23-893
SUD 药物开发的药代动力学和药效动力学试验。
- 批准号:
10937538 - 财政年份:2023
- 资助金额:
$ 4.93万 - 项目类别:
PHASE I COCAINE DRUG INTERACTION STUDY. TO6. NIDA PHARMACOKINETIC ANALYSIS RESOURCE CENTER. 08/10/2023 - 02/09/2025. NIDA REF. NO. N01DA-19-8947.
第一阶段可卡因药物相互作用研究。
- 批准号:
10937276 - 财政年份:2023
- 资助金额:
$ 4.93万 - 项目类别:
Structure/Function Drug Interaction Studies on Voltage-Gated Sodium Channels
电压门控钠通道的结构/功能药物相互作用研究
- 批准号:
BB/V018035/1 - 财政年份:2022
- 资助金额:
$ 4.93万 - 项目类别:
Research Grant
Investigation of the Immune-Mediated Drug-Drug Interaction Potential of Immune Checkpoint Inhibitors
免疫检查点抑制剂免疫介导的药物相互作用潜力的研究
- 批准号:
10677895 - 财政年份:2022
- 资助金额:
$ 4.93万 - 项目类别:
Genomic and drug-drug interaction mechanisms of interindividual variability in drug disposition
药物处置个体差异的基因组和药物相互作用机制
- 批准号:
10406564 - 财政年份:2022
- 资助金额:
$ 4.93万 - 项目类别:
Investigation of the Immune-Mediated Drug-Drug Interaction Potential of Immune Checkpoint Inhibitors
免疫检查点抑制剂免疫介导的药物相互作用潜力的研究
- 批准号:
10506483 - 财政年份:2022
- 资助金额:
$ 4.93万 - 项目类别:
Genomic and drug-drug interaction mechanisms of interindividual variability in drug disposition
药物处置个体差异的基因组和药物相互作用机制
- 批准号:
10598140 - 财政年份:2022
- 资助金额:
$ 4.93万 - 项目类别:
Identification and evaluation of novel biomarkers by metabolome analysis for drug interaction on renal drug transporters
通过代谢组分析鉴定和评估肾脏药物转运蛋白药物相互作用的新型生物标志物
- 批准号:
22K15311 - 财政年份:2022
- 资助金额:
$ 4.93万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unravelling the mechanism of acai BDS-anticancer drug interaction: A preliminary approach
揭示巴西莓 BDS 与抗癌药物相互作用的机制:初步方法
- 批准号:
10291596 - 财政年份:2021
- 资助金额:
$ 4.93万 - 项目类别:
DDI-on-a-chip: an optimized liver microphysiological system and microenvironment for complex drug-drug interaction studies
DDI-on-a-chip:用于复杂药物相互作用研究的优化肝脏微生理系统和微环境
- 批准号:
10324897 - 财政年份:2021
- 资助金额:
$ 4.93万 - 项目类别:














{{item.name}}会员




